FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:125-137 July 13, 2006 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Stefanick, M. L. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established.

Methods We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and followed them for a median of 5.6 years. The two primary outcomes were coronary events (i.e., death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome) and invasive breast cancer.

Results As compared with placebo, raloxifene had no significant effect on the risk of primary coronary events (533 vs. 553 events; hazard ratio, 0.95; 95 percent confidence interval, 0.84 to 1.07), and it reduced the risk of invasive breast cancer (40 vs. 70 events; hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute risk reduction, 1.2 invasive breast cancers per 1000 women treated for one year); the benefit was primarily due to a reduced risk of estrogen-receptor–positive invasive breast cancers. There was no significant difference in the rates of death from any cause or total stroke according to group assignment, but raloxifene was associated with an increased risk of fatal stroke (59 vs. 39 events; hazard ratio, 1.49; 95 percent confidence interval, 1.00 to 2.24; absolute risk increase, 0.7 per 1000 woman-years) and venous thromboembolism (103 vs. 71 events; hazard ratio, 1.44; 95 percent confidence interval, 1.06 to 1.95; absolute risk increase, 1.2 per 1000 woman-years). Raloxifene reduced the risk of clinical vertebral fractures (64 vs. 97 events; hazard ratio, 0.65; 95 percent confidence interval, 0.47 to 0.89; absolute risk reduction, 1.3 per 1000).

Conclusions Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke. (ClinicalTrials.gov number, NCT00190593.)

Source Information

From the Department of Family and Preventive Medicine, University of California, San Diego, La Jolla (E.B.-C.); the Department of Medicine, Columbia University College of Physicians and Surgeons, New York (L.M.); the Department of Cardiac Medicine, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London (P.C.); Lilly Research Laboratories, Eli Lilly, Indianapolis (M.J.G., M.A.M.); the Departments of Epidemiology and Biostatistics and Medicine, University of California, San Francisco, and the San Francisco Veterans Affairs Medical Center, San Francisco (D.G.); the Department of Epidemiology and Health Promotion, School of Public Health, Brussels Free University, Brussels (M.K.); and Emory University School of Medicine, Atlanta (N.K.W.).

Address reprint requests to Dr. Barrett-Connor at the Department of Family and Preventive Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0607, or at ebarrettconnor{at}ucsd.edu.

Full Text of this Article

This article has been cited by other articles:

• Thomsen, A., Kolesar, J. M. (2008). Chemoprevention of breast cancer. Am J Health Syst Pharm 65: 2221-2228 [Abstract] [Full Text]  
• Mahoney, M. C., Bevers, T., Linos, E., Willett, W. C. (2008). Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction. CA Cancer J Clin 0: CA.2008.0016v1-CA.2008.0016 [Abstract] [Full Text]  
• Jacobson, B. C., Moy, B., Colditz, G. A., Fuchs, C. S. (2008). Postmenopausal Hormone Use and Symptoms of Gastroesophageal Reflux. Arch Intern Med 168: 1798-1804 [Abstract] [Full Text]  
• Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., Bilezikian, J., Kerzberg, E. M., Johnson, S., Zanchetta, J., Grobbee, D. E., Seifert, W., Eastell, R., the LIFT Trial Investigators, (2008). The Effects of Tibolone in Older Postmenopausal Women. NEJM 359: 697-708 [Abstract] [Full Text]  
• Rathbun, S. (2008). Venous thromboembolism in women. Vasc Med 13: 255-266 [Abstract]  
• Jordan, V. C. (2008). The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?. JCO 26: 3073-3082 [Abstract] [Full Text]  
• Grady, D., Cauley, J. A., Geiger, M. J., Kornitzer, M., Mosca, L., Collins, P., Wenger, N. K., Song, J., Mershon, J., Barrett-Connor, E., For the Raloxifene Use for The Heart Trial Investi, (2008). Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk. JNCI J Natl Cancer Inst 100: 854-861 [Abstract] [Full Text]  
• Jordan, V. C. (2008). The Rise of Raloxifene and the Fall of Invasive Breast Cancer. JNCI J Natl Cancer Inst 100: 831-833 [Full Text]  
• Stock, J. L., Mershon, J. L., Schoenfeld, M. J. (2008). Review of Comparative Effectiveness of Treatments to Prevent Fractures. ANN INTERN MED 148: 885-885 [Full Text]  
• Gehrig, L., Lane, J., O'Connor, M. I. (2008). Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons. JBJS 90: 1362-1374 [Full Text]  
• Miller, V. M., Duckles, S. P. (2008). Vascular Actions of Estrogens: Functional Implications. Pharmacol. Rev. 60: 210-241 [Abstract] [Full Text]  
• Crivellari, D., Sun, Z., Coates, A. S., Price, K. N., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R. J., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., Lang, I., Del Mastro, L., Gladieff, L., Rabaglio, M., Smith, I. E., Chirgwin, J. H., Goldhirsch, A. (2008). Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. JCO 26: 1972-1979 [Abstract] [Full Text]  
• Smith, M. R., Malkowicz, S. B., Chu, F., Forrest, J., Sieber, P., Barnette, K. G., Rodriquez, D., Steiner, M. S. (2008). Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study. JCO 26: 1824-1829 [Abstract] [Full Text]  
• Rees, M., Stevenson, J., on behalf of the British Menopause Society Council, (2008). Primary prevention of coronary heart disease in women. Menopause Int 14: 40-45 [Abstract] [Full Text]  
• MacLaughlin, E. J., Raehl, C. L. (2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm 65: 343-357 [Full Text]  
• Alonso-Coello, P., Garcia-Franco, A. L., Guyatt, G., Moynihan, R. (2008). Drugs for pre-osteoporosis: prevention or disease mongering?. BMJ 336: 126-129 [Full Text]  
• Jordan, V. C., O'Malley, B. W. (2007). Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. JCO 25: 5815-5824 [Abstract] [Full Text]  
• Jadoul, M. (2007). Towards the prevention of bone fractures in dialysed patients?. Nephrol Dial Transplant 22: 3377-3380 [Full Text]  
• Jordan, V. C. (2007). Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point. Cancer Epidemiol. Biomarkers Prev. 16: 2207-2209 [Full Text]  
• Fabian, C. (2007). Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A Tale of Two Choices Counterpoint. Cancer Epidemiol. Biomarkers Prev. 16: 2210-2212 [Full Text]  
• Li, Y., Zhang, Y., Hill, J., Shen, Q., Kim, H.-T., Xu, X., Hilsenbeck, S. G., Bissonnette, R. P., Lamph, W. W., Brown, P. H. (2007). The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor Negative Tumors in MMTV-erbB2 Mice. Clin. Cancer Res. 13: 6224-6231 [Abstract] [Full Text]  
• Beckley, E. T. (2007). Women Need Tailored CHD Prevention. DOC News 4: 5-5 [Full Text]  
• Wyeth, J., Green, L., Avigan, M. (2007). U.S. Food and Drug Administration Analysis of Strokes Associated With Raloxifene. Obstet Gynecol 109: 999-999 [Full Text]  
• Jordan, V. C. (2007). SERMs: Meeting the Promise of Multifunctional Medicines. JNCI J Natl Cancer Inst 99: 350-356 [Abstract] [Full Text]  
• Shoback, D. (2007). Update in Osteoporosis and Metabolic Bone Disorders. J. Clin. Endocrinol. Metab. 92: 747-753 [Abstract] [Full Text]  
• Powles, T. J., Ashley, S., Tidy, A., Smith, I. E., Dowsett, M. (2007). Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial. JNCI J Natl Cancer Inst 99: 283-290 [Abstract] [Full Text]  
• Cummings, S. R. (2006). A 55-Year-Old Woman With Osteopenia. JAMA 296: 2601-2610 [Abstract] [Full Text]  
• Stearns, V. (2006). Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk. Evid. Based Med. 11: 177-177 [Full Text]  
• Thacker, H. L (2006). Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk. Evid. Based Med. 11: 178-178 [Full Text]  
• Pinna, C., Bolego, C., Sanvito, P., Pelosi, V., Baetta, R., Corsini, A., Gaion, R. M., Cignarella, A. (2006). Raloxifene Elicits Combined Rapid Vasorelaxation and Long-Term Anti-Inflammatory Actions in Rat Aorta. J. Pharmacol. Exp. Ther. 319: 1444-1451 [Abstract] [Full Text]  
• Meadows, E. S., Stock, J., Johnston, J. A. (2006). Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies.. Med Decis Making 26: 633-635  
• Johnson, K. A. (2006). The SERM of My Dreams.. J. Clin. Endocrinol. Metab. 91: 3754-3756 [Full Text]  
• Bolego, C., Vegeto, E., Pinna, C., Maggi, A., Cignarella, A. (2006). Selective Agonists of Estrogen Receptor Isoforms: New Perspectives for Cardiovascular Disease. Arterioscler. Thromb. Vasc. Bio. 26: 2192-2199 [Abstract] [Full Text]  
• Lippman, M. E., Cummings, S. R., Disch, D. P., Mershon, J. L., Dowsett, S. A., Cauley, J. A., Martino, S. (2006). Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk. Clin. Cancer Res. 12: 5242-5247 [Abstract] [Full Text]  
• (2006). Raloxifene Does Not Prevent Heart Disease. Journal Watch Cardiology 2006: 2-2 [Full Text]  
• (2006). Raloxifene and Risk for Cardiovascular Events and Breast Cancer. JWatch Women's Health 2006: 1-1 [Full Text]  
• Tonks, A. (2006). What's new in the other general journals. BMJ 333: 192-193 [Full Text]  
• Stefanick, M. L. (2006). Risk-benefit profiles of raloxifene for women.. NEJM 355: 190-192 [Full Text]  
• (2006). Outcomes with Raloxifene in Women with Above-Average Coronary Risk. JWatch General 2006: 1-1 [Full Text]